DNTH

20.85

4.77% 0.95

Handel nachbörslich: 20.85

Dianthus Therapeutics Inc (DNTH)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$19.90

Offen:

$20.01

24-Stunden-Volumen:

242.44K

Relative Volume:

0.76

Marktkapitalisierung:

$670.54M

Einnahmen:

$4.12M

Nettoeinkommen (Verlust:

$-56.68M

KGV:

-3.7616

EPS:

-5.5429

Netto-Cashflow:

$-51.44M

1W Leistung:

+2.26%

1M Leistung:

+3.94%

6M Leistung:

-13.59%

1J Leistung:

-21.23%

1-Tages-Spanne:

$19.75

$21.18

1-Wochen-Bereich:

$18.08

$21.18

52-Wochen-Spanne:

$13.37

$32.27

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Firmenname

Dianthus Therapeutics Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

929-999-4055

Adresse

7 TIMES SQUARE, NEW YORK

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

DNTH's Discussions on Twitter

Vergleichen Sie DNTH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DNTH Dianthus Therapeutics Inc	20.85	607.88M	4.12M	-56.68M	-51.44M	-5.5429
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.42B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	57.86B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	57.02B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.10B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.45B	3.81B	-644.79M	-669.77M	-6.24

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-02	Eingeleitet	William Blair	Outperform
2024-12-20	Eingeleitet	TD Cowen	Buy
2024-10-03	Eingeleitet	Oppenheimer	Outperform
2024-07-26	Eingeleitet	Robert W. Baird	Outperform
2024-06-27	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-16	Eingeleitet	H.C. Wainwright	Buy
2024-02-15	Eingeleitet	Stifel	Buy
2023-12-26	Eingeleitet	Jefferies	Buy
2023-11-22	Eingeleitet	Wedbush	Outperform
2023-10-30	Eingeleitet	Guggenheim	Buy
2023-09-28	Eingeleitet	Raymond James	Outperform
2022-08-25	Herabstufung	Goldman	Buy → Neutral
2022-01-06	Hochstufung	Goldman	Neutral → Buy
2021-08-20	Fortgesetzt	Goldman	Neutral
2021-08-03	Herabstufung	JP Morgan	Overweight → Neutral
2021-07-22	Bestätigt	B. Riley Securities	Buy
2021-06-29	Eingeleitet	Cantor Fitzgerald	Overweight
2021-06-15	Eingeleitet	BTIG Research	Buy
2021-05-18	Eingeleitet	B. Riley Securities	Buy
2021-01-07	Eingeleitet	Mizuho	Buy
2020-06-08	Hochstufung	Goldman	Neutral → Buy
2019-03-25	Herabstufung	Goldman	Buy → Neutral
2019-03-15	Eingeleitet	Raymond James	Outperform

Alle ansehen

Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten

10:01 AM

Is this a good reentry point in Dianthus Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser

10:01 AM

09:25 AM

Dianthus Therapeutics Inc.’s volatility index tracking explainedAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser

09:25 AM

09:24 AM

Dianthus Therapeutics Inc. stock trend forecast2025 Year in Review & Real-Time Stock Entry Alerts - Newser

09:24 AM

05:34 AM

What earnings revisions data tells us about Dianthus Therapeutics Inc.2025 Key Lessons & Breakout Confirmation Alerts - Newser

05:34 AM

05:04 AM

How to forecast Dianthus Therapeutics Inc. trends using time seriesMarket Growth Review & Consistent Profit Focused Trading Strategies - Newser

05:04 AM

03:31 AM

Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.Long Setup & Technical Entry and Exit Alerts - Newser

03:31 AM

03:28 AM

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $53.00 Consensus Target Price from Brokerages - MarketBeat

03:28 AM

01:22 AM

Backtesting results for Dianthus Therapeutics Inc. trading strategiesWeekly Stock Recap & Precise Entry and Exit Recommendations - Newser

01:22 AM

12:53 PM

Can you recover from losses in Dianthus Therapeutics Inc. [Quarterly Performance Summary]Free Reliable Trade Execution Plans - Newser

12:53 PM

12:23 PM

How institutional ownership impacts Dianthus Therapeutics Inc. stock [July 2025 Rallies]Free Community Verified Trade Signals - Newser

12:23 PM

Aug 12, 2025

Is Dianthus Therapeutics Inc. stock poised for growthFree Weekly Setup With 3x Return Potential - Newser

Aug 12, 2025

Custom watchlist performance reports with Dianthus Therapeutics Inc.Strong Buy Opportunity with Volume Support - Newser

Aug 12, 2025

What is William Blair's Estimate for DNTH Q1 Earnings? - MarketBeat

Aug 12, 2025

Relative strength of Dianthus Therapeutics Inc. in sector analysisDay Trading Plan with Entry Risk Management - Newser

Aug 12, 2025

Has Dianthus Therapeutics Inc. formed a bullish divergenceDay Trading Setup and Momentum Analysis - Newser

Aug 12, 2025

Aug 11, 2025

How moving averages guide Dianthus Therapeutics Inc. tradingFree Triple Return Setup with Risk Control - Newser

Aug 11, 2025

How institutional ownership impacts Dianthus Therapeutics Inc. stockDaily Profit Watch With Forecast Confidence - Newser

Aug 11, 2025

Aug 10, 2025

Will earnings trigger a reversal in Dianthus Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser

Aug 10, 2025

Dianthus Therapeutics (DNTH) to Release Earnings on Thursday - MarketBeat

Aug 10, 2025

Key External Factors That Drive Dianthus Therapeutics Inc. Stock Price MovementsValue Holding Return Summary With Outlook - Newser

Aug 10, 2025

Real time breakdown of Dianthus Therapeutics Inc. stock performancePortfolio Risk Summary & Technical Entry and Exit Alerts - Newser

Aug 10, 2025

Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionFree Accurate Buy Point for Momentum Stocks - Newser

Aug 10, 2025

Aug 09, 2025

What makes Dianthus Therapeutics Inc. stock price move sharplyFree Consistent Gain Investment Strategies - Newser

Aug 09, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Aug 09, 2025

Aug 08, 2025

Is Dianthus Therapeutics Inc. still worth holding after the dipFree Reliable Investment Entry Point Signals - Newser

Aug 08, 2025